Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

HRS-5041, an androgen receptor degrader, in metastatic castration-resistant prostate cancer: A phase 1, multicenter, first-in-human study.

Wei Xue, Chaochao Liang, Jiahua Pan et al. Jun 01, 2026 pp. 3112-3112 10.1200/jco.2026.44.16_suppl.3112

3112 Background: ADT plus NHA have been approved for PC of different stages. However, patients (pts) inevitably develop dr...

Prior authorization utilization, administrative burden, and implications for timely care.

Yazmin Odia, Julie Keegan-Strosser, Juan Alberto Marte Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23035

e23035 Background: U.S. payers widely use prior authorization (PA) to manage utilization of high-cost therapies. Although...

Neoadjuvant versus adjuvant chemotherapy for resectable high-grade soft tissue sarcoma: A real-world propensity-matched survival analysis.

Mohammed Aloqaily, Aaron Ciner, Dan Kunaprayoon et al. Jun 01, 2026 pp. 11585-11585 10.1200/jco.2026.44.16_suppl.11585

11585 Background: High-grade soft tissue sarcomas are aggressive malignancies for which complete surgical resection remain...

Temporal trends in adherence to adjuvant endocrine therapy across age groups in hormone receptor–positive breast cancer.

Michael M. Caplan, David DeStephano, Claire M. Sathe et al. Jun 01, 2026 pp. 634-634 10.1200/jco.2026.44.16_suppl.634

634 Background: Adjuvant endocrine therapy (ET) reduces recurrence and mortality in hormone receptor–positive breast cance...

Electrolyte abnormalities and arrhythmia-associated inpatient deterioration in hospitalized cancer patients: National patterns in the National Inpatient Sample, 2018–2022.

Carter Taysom, Ramaditya Srinivasmurthy, Riccesha Hattin et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23162

e23162 Background: Electrolyte abnormalities are frequent during cancer hospitalizations, but their independent associatio...

Neoadjuvant immunotherapy combined with radiochemotherapy vs chemotherapy alone in pMMR colon cancers: The TORCH-C randomized phase 2 clinical trial.

Hui Zhang, Yaqi Li, Fan Xia et al. Jun 01, 2026 pp. 3634-3634 10.1200/jco.2026.44.16_suppl.3634

3634 Background: The prognosis for locally advanced colon cancer (LACC) with bulky nodal disease and/or clinically T4 stag...

The influence of exercise on the mediational relationship between chemotherapy-induced sensory neuropathy and cancer-related fatigue: A nationwide phase II RCT in 111 patients receiving chemotherapy.

Po-Ju Lin, Hongying Sun, Chin-Shang Li et al. Jun 01, 2026 pp. 12151-12151 10.1200/jco.2026.44.16_suppl.12151

12151 Background: Cancer-related fatigue (CRF) and chemotherapy-induced sensory neuropathy (e.g., numbness, tingling, and...

Oncologic equivalence of brand-name vs generic imatinib in neoadjuvant <i>KIT</i> exon 11 GIST: A real-world international cohort study.

Tannaz Ranjbarian, Michela Del Simone, Mark Antkowiak et al. Jun 01, 2026 pp. 11535-11535 10.1200/jco.2026.44.16_suppl.11535

11535 Background: Neoadjuvant imatinib is routinely used to facilitate resection of localized gastrointestinal stromal tum...

Fatty acid degradation (FAD)–guided comprehensive therapy for unresectable hepatocellular carcinoma: A prospective phase II study (FAD-HCC-01).

Decai Yu, Binghua Li, Yuan Cheng Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps4256

TPS4256 Background: Hepatocellular carcinoma (HCC) exhibits marked molecular and metabolic heterogeneity, leading to varia...

Association of healthcare delivery model with stage at diagnosis of pancreatic cancer.

Ariana Liane Flores, Matthew T. Newman, Jing Zhang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23126

e23126 Background: Pancreatic cancer is a leading cause of cancer mortality in the U.S., with a 5-year relative survival r...

A phase 1/2 first-in-human study of TH9619 in patients with advanced refractory solid tumors (ODIN).

Víctor Moreno, Antoine Hollebecque, Irene Braña et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps3165

TPS3165 Background: TH9619 is a first-in-class, potent, small-molecule, and dual inhibitor of methylene-tetrahydrofolate d...

A deep-learning model for immunotherapy efficacy prediction directly from H&amp;E slides in head-neck squamous cell carcinoma (HNSCC).

Tien-Hua Chen, Yu-Tung Chen, Gal Dinstag et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18006

e18006 Background: Immunotherapy (IO) has emerged as the standard of care for recurrent and metastatic HNSCC. However, con...

Prevalence and risk of anemia and iron deficiency anemia in premenopausal women with breast cancer: A single-center retrospective study.

Zhan Rong, Lea N. Baer Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24166

e24166 Background: Anemia is common in breast cancer patients at diagnosis and during treatment. It has been associated wi...

Trends and in-hospital outcomes of multiple myeloma in autoimmune rheumatic disease hospitalizations: A National Inpatient Sample analysis, 2016–2022.

Naina Kumari, Barkha Kumari, Srijani Thannir et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19577

e19577 Background: Multiple myeloma (MM) is associated with immune dysregulation and substantial inpatient morbidity. Auto...

From SMARCA4 deficiency to tumor-agnostic therapies: A single-center retrospective study for 66 patients with SMARCA4-deficient tumors.

Yang Liu, Yin-Miao Bai, Zhi-Hui Liu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15206

e15206 Background: SMARCA4-deficient tumors represent a newly defined category of malignancies in recent years, characteri...

Aspirin use and outcomes with immune checkpoint inhibitors in metastatic cancer.

Satı Coskun Yazgan, Nursima Kanburoglu, Beliz Bahar Karaoğlan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14584

e14584 Background: Aspirin (ASA) may modulate antitumor immunity. We evaluated the association between concomitant ASA use...

Genomic clonality analysis of patients with metastatic lung-limited non–small cell lung carcinoma (NSCLC) who underwent double lung transplantation (DLT) across timepoints and tumor region.

Sang Hwa Kim, Young Kwang Chae, Liam Il-Young Chung et al. Jun 01, 2026 pp. 8658-8658 10.1200/jco.2026.44.16_suppl.8658

8658 Background: Double lung transplantation (DLT) registry aimed for lung-limited malignancies (DREAM) study (NCT05671887...

Publication pathways and impact metrics of African cancer research presented at major international conferences.

Phocas Havugimana, Vincent Kwizera, Fidel Rubagumya Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23391

e23391 Background: Despite bearing a disproportionate share of the global cancer burden, African researchers remain under-...

Intra-arterial chemotherapy for retinoblastoma: Treatment outcomes and globe preservation—A tertiary cancer center experience in India.

Vijay Anand Reddy Palkonda, Santosh Honavar, Sri Sai Tejaswini Muddana et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12622

e12622 Background: Intra-arterial chemotherapy (IAC) represents an important globe-preserving strategy for advanced retino...

Phase II study of liposomal irinotecan in combination with cisplatin and bevacizumab for high-grade recurrent glioma.

Weiyan Shi, Jianfeng Wang, Rui Liu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14059

e14059 Background: For patients with high-grade glioma, the most common and aggressive primary brain tumor in adults, dise...

Different roles of SALL4 and OCT3/4 in the development and evolving processes of benign and malignant germ cells.

Kevin Juan Zhang, Jason Hafron, Ping Zhang Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17006

e17006 Background: In gonadogenesis, OCT3/4 and SALL4 are expressed in early germ cells and are critical for maintaining t...

Genotype-directed targeted therapy combined with HAIC and tislelizumab for microsatellite-stable colorectal cancer liver metastasis refractory to multiple-line systemic therapy (proof-of-concept SALVLIVE trial): An interim analysis.

Kanglian Zheng, Liang Xu, Guang Cao et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15545

e15545 Background: The prognosis of microsatellite-stable (MSS) colorectal cancer liver metastasis (CRCLM) refractory to s...

ADELA: A double-blind, placebo-controlled, randomized phase 3 trial of elacestrant (Ela) + everolimus (EVE) versus elacestrant + placebo in ER+/HER2− advanced breast cancer (aBC) patients with <i>ESR1</i> -mutated tumors progressing on endocrine therapy (ET) + CDK4/6i.

Antonio Llombart-Cussac, José Manuel Pérez García, Elena López-Miranda et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps1154

TPS1154 Background: ET+CDK4/6i is the standard-of-care (SOC) in 1L ER+/HER2- aBC; however, tumors eventually develop resis...

Impact of volunteer-integrated palliative home visits on psychological well-being among metastatic breast cancer patients in northern Malaysia.

Siti Khairizan Binti Rahim, Hairunnisa binti Mohamad Ibrahim, Siti Nooraini Mohamad Yusof et al. Jun 01, 2026 pp. 12090-12090 10.1200/jco.2026.44.16_suppl.12090

12090 Background: Metastatic breast cancer patients face overlooked psychosocial challenges, mitigated through home visits...

Insights through the renal lens: Clinical outcomes of newly diagnosed multiple myeloma patients with and without renal impairment in a resource-limited setting.

Anoud Khan, Saqib Raza Khan, Munira Moosajee et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19531

e19531 Background: Renal impairment (RI) is a frequent and clinically significant complication of newly diagnosed multiple...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page